Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811161 | 0.92 | MAOB (0.42) | MAOBDRD2HTR4HTR1A | |
| SCHEMBL6811489 | 0.86 | SLC6A4 (0.36) | DRD2HTR4HTR1A | |
| SCHEMBL6811053 | 0.83 | DRD2 (0.45) | DRD2HTR1A | |
| SCHEMBL6710778 | 0.81 | DRD2 (0.58) | DRD2HTR1A | |
| SCHEMBL5937286 | 0.81 | HTR1A (0.51) | DRD2HTR1A | |
| SCHEMBL6806208 | 0.79 | DRD2 (0.51) | MAOBDRD2HTR1A | |
| SCHEMBL6787753 | 0.78 | DRD2 (0.47) | DRD2HTR1A | |
| SCHEMBL6811433 | 0.78 | DRD4 (0.39) | DRD2 | |
| SCHEMBL6797318 | 0.76 | DRD2 (0.45) | DRD2HTR1A | |
| SCHEMBL6802933 | 0.75 | SLC2A1 (0.44) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1351935-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055495-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | MAOB 2742/4885DRD2 269/4885HTR4 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.